

- 27 -

**CLAIMS**

1. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of the formula  $X_1$ -His-Lys-X-Lys- $X_2$  wherein

X is any amino acid,

$X_1$  is from zero to twelve amino acids, and

$X_2$  is from zero to twelve amino acids,

and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

2. The composition of claim 1 wherein

$X_1$  is from zero to six amino acids, and

$X_2$  is from zero to six amino acids.

3. The composition of claim 1 wherein X is selected from the group consisting of Ala, Leu, Ile, Val, Pro, Phe, Trp, Met, Ser, Thr, Tyr, Asn, Gln, Cys, and Gly.

4. The composition of claim 3 wherein X is Asn, Phe or His.

5. The composition of claim 1 wherein

$X_1$  is

(i) zero amino acids or

(ii) the segment His-Gly-His-Glu-Gln-Gln-His-

- 28 -

Gly-Leu-Gly-His-Gly (SEQ ID NO:1) , or N-terminal truncation fragment thereof containing at least one amino acid, and

5

$X_2$  is

(i) zero amino acids, or

(ii) the segment Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:2) , or C-terminal truncation fragment thereof containing at least one amino acid.

10

6. The composition of claim 5 wherein X is Asn, Phe or His.

7. The composition of claim 1 wherein the compound has substantial amino acid sequence homology to the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:5) .

15

8. The composition of claim 1 wherein the compound has the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:5).

20

9. The composition of claim 1 wherein the compound has the amino acid sequence Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His (SEQ ID NO:7) .

25

10. The composition of claim 1 wherein

$X_1$  is

(i) zero amino acids, or

(ii) the segment Gly-His-Lys-His-Lys-His-Gly-His-Gly-His-Gly-Lys (SEQ ID NO:3) or N-terminal

- 29 -

truncation fragment thereof containing at least one amino acid, and

X<sub>2</sub> is

- 5 (i) zero amino acids, or  
(ii) the segment Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:4) or C-terminal truncation fragment thereof containing at least one amino acid.

10 11. The composition of claim 10 wherein X is Asn, Phe or His.

12. The composition of claim 10 having substantial amino acid sequence homology to the amino acid sequence Gly-His-Lys-His-Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:6).

15 13. The composition of claim 10 having the amino acid sequence Gly-His-Lys-His-Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:6).

20 14. The composition of claim 10 having the amino acid sequence Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn (SEQ ID NO:8).

15. The composition of claim 10 having the amino acid sequence His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:9).

25 16. A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of a composition according to claim 1.

66001 216/2460

2/1/05

- 30 -

17. A method of inhibiting endothelial cell proliferation comprising administering to a mammal an effective amount of a composition according to claim 1.

5 18. A method of inducing endothelial cell apoptosis comprising administering to a mammal an effective amount of a composition according to claim 1.

19. A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of two-chain high molecular weight kininogen.

10 20. A method of inhibiting endothelial cell proliferation comprising administering to a mammal an effective amount of two-chain high molecular weight kininogen.

15 21. A method of inducing endothelial cell apoptosis comprising administering to a mammal an effective amount of two-chain high molecular weight kininogen.

22. A method of inhibiting angiogenesis comprising administering to a mammal an effective amount of single-chain high molecular weight kininogen.

20 23. A method of inhibiting endothelial cell proliferation comprising contacting endothelial cells with a compound of the formula  $X_1\text{-His-Lys-X-Lys-X}_2$  wherein

X is any amino acid,

$X_1$  is from zero to twelve amino acids, and

$X_2$  is from zero to twelve amino acids,

25 and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

24. The method of any of claim 23 wherein

66001-2162450

- 31 -

$X_1$  is from zero to six amino acids, and  
 $X_2$  is from zero to six amino acids.

25. The method of claim 23 wherein X is selected from  
5 the group consisting of Ala, Leu, Ile, Val, Pro, Phe, Trp, Met, Ser, Thr,  
Tyr, Asn, Gln, Cys, and Gly.

26. The method of claim 25 wherein X is Asn, Phe or  
His.

27. The method of claim 23 wherein

$X_1$  is

(i) zero amino acids, or  
(ii) the segment His-Gly-His-Glu-Gln-Gln-His-  
10 Gly-Leu-Gly-His-Gly (SEQ ID NO:1), or N-terminal  
15 truncation fragment thereof containing at least one  
amino acid, and

$X_2$  is

(i) zero amino acids, or  
(ii) the segment Leu-Asp-Asp-Asp-Leu-Glu-  
20 His-Gln-Gly-Gly-His-Val (SEQ ID NO:2), or C-  
terminal truncation fragment thereof containing at  
least one amino acid.

28. The method of claim 23 wherein

$X_1$  is

(i) zero amino acids, or  
25 (ii) the segment Gly-His-Lys-His-Lys-His-Gly-  
His-Gly-His-Gly-Lys (SEQ ID NO:3) or N-terminal  
truncation fragment thereof containing at least one  
amino acid, and

6607-262260

- 32 -

$X_2$  is

- (i) zero amino acids, or
- (ii) the segment Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:4) or C-terminal truncation fragment thereof containing at least one amino acid.

5

29. The method according to claim 27 wherein inhibition of proliferation includes apoptosis of the endothelial cells.

30. A compound of the formula  $X_1$ -His-Lys-X-Lys- $X_2$

wherein

10

$X_1$  is

the segment His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly (SEQ ID NO:1), or N-terminal truncation fragment thereof containing at least one amino acid, and

15

$X_2$  is

- (i) zero amino acids, or
- (ii) the segment Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:2), or C-terminal truncation fragment thereof containing at least one amino acid,

20

and wherein said compound optionally comprises an amino-terminal and/or carboxy-terminal protecting group.

31. The compound of claim 30 wherein X is Asn, Phe or His.

25

32. The compound of claim 30 having substantial amino acid sequence homology to the amino acid sequence His-Gly-His-Glu-Gln-Gln-His-Gly-Leu-Gly-His-Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His-Val (SEQ ID NO:5).

30

- 33 -

33. The compound of claim 30 having the amino acid sequence Gly-His-Lys-Phe-Lys-Leu-Asp-Asp-Asp-Leu-Glu-His-Gln-Gly-Gly-His (SEQ ID NO:7).

May 5  
34. The compound having the amino acid sequence Lys-His-Gly-His-Gly-His-Gly-Lys-His-Lys-Asn-Lys-Gly-Lys-Lys-Asn (SEQ ID NO:8).

add a1  
35. The compound having the amino acid sequence His-Lys-Asn-Lys-Gly-Lys-Lys-Asn-Gly-Lys-His-Asn-Gly-Trp-Lys-Thr (SEQ ID NO:9).

66011-2162460